Definitive Healthcare Corp. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Krantz Jason Ronald, was filed 09 Nov 2022.
Definitive Healthcare Corp.: what insiders have been doing
Definitive Healthcare Corp. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). 10 insiders have disclosed 27 filings since 8 November 2025.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 3,182 companies) published 24 filings over the same period, against 27 filings here. The full history, which starts in 2021, counts 2 purchases against 17 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 241.5 m USD and net income of -138.9 m USD.
There has been no open-market purchase by an insider of Definitive Healthcare Corp. for at least a year. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -37.5%Entry US$11.49 · Close at T+365 US$7.18
- -45.5%Entry US$21.57 · Close at T+365 US$11.75
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- 12,166 shares@ US$1.120.011% mcap0.2% of flowClass A Common StockSEC:0001193125-26-445309:0
- 1,881 shares@ US$1.120.0018% mcap2.3% of flowClass A Common StockSEC:0001193125-26-445308:0
- 2,626,263 shares0Class A Common StockSEC:0001193125-26-434193:0
- 12,542 shares@ US$0.93610.012% mcap13.2% of flowClass A Common StockSEC:0001193125-26-414095:0
- 7,729 shares@ US$0.93610.0072% mcap22.9% of flowClass A Common StockSEC:0001193125-26-414092:0
- 41,093 shares@ US$0.90230.030% mcap40.7% of flowClass A Common StockSEC:0001193125-26-381870:0
- 1,881 shares@ US$0.68230.0012% mcap1.4% of flowClass A Common StockSEC:0001193125-26-332755:0
- 12,166 shares@ US$0.68230.0076% mcap0.1% of flowClass A Common StockSEC:0001193125-26-332758:0
- 37,593 shares@ US$0.800.028% mcap3.2% of flowClass A Common StockSEC:0001193125-26-296168:0
- 30,591 shares@ US$0.800.023% mcap100.0% of flowClass A Common StockSEC:0001193125-26-296167:0
- 189,190 shares0Class A Common StockSEC:0001193125-26-263150:0
- 189,190 shares0Class A Common StockSEC:0001193125-26-262529:0
- 189,190 shares0Class A Common StockSEC:0001193125-26-261833:0
- 189,190 shares0Class A Common StockSEC:0001193125-26-261948:0
- 37,593 shares@ US$1.094.2% of flowClass A Common StockSEC:0001193125-26-142183:0
- 45,154 shares@ US$1.090.7% of flowClass A Common StockSEC:0001193125-26-142181:0
- 175,524 shares@ US$1.2822.8% of flowClass A Common StockSEC:0001193125-26-088137:0
- 631,068 shares0Class A Common StockSEC:0001193125-26-077209:0
- 481,505 shares0Class A Common StockSEC:0001193125-26-077200:0
- 733,301 shares0Class A Common StockSEC:0001193125-26-077194:0
- 242,719 shares0Class A Common StockSEC:0001193125-26-077183:0
- 1,735,437 shares0Class A Common StockSEC:0001193125-26-077188:0
- 44,545 shares@ US$2.321.4% of flowClass A Common StockSEC:0001193125-26-035552:0
- 1,469 shares@ US$2.324.2% of flowClass A Common StockSEC:0001193125-26-035486:0
- 195,313 shares0Class A Common StockSEC:0001193125-26-006286:0
25 of 231 declarations
About Definitive Healthcare Corp.
Definitive Healthcare Corp. (Nasdaq: DH) is a U.S.-listed company traded on the NASDAQ market in the United States, focused on healthcare data, analytics, and commercial intelligence. For international investors, the company is best understood as a specialized SaaS and data-infrastructure provider rather than a conventional healthcare operator. Its platform helps customers understand the healthcare ecosystem more clearly by organizing proprietary and public data into actionable intelligence on providers, clinicians, claims, experts, and market opportunities. The company was founded in 2011, and Definitive Healthcare Corp. was later formed in 2021 in connection with the IPO structure. Its headquarters are in Framingham, Massachusetts, United States, with additional operations in the U.S., Sweden, and India.
At the core of the business is a multi-tenant data platform that supports a suite of products used by commercial, marketing, strategy, and operations teams across healthcare-adjacent industries. The product portfolio includes market intelligence, customer targeting, patient-cohort analytics, performance monitoring, expert identification, and workflow tools. Key product families include Atlas, Latitude, Passport, and Monocl, which serve different use cases such as healthcare market mapping, cohort discovery, life-science commercial planning, promotional analytics, and medical/expert network identification. The customer base is broad and includes life sciences companies, medical device firms, healthcare providers, software and IT vendors, consulting groups, financial services firms, staffing companies, and other businesses that sell into or operate around healthcare.
Read moreShow less
From a competitive standpoint, Definitive Healthcare occupies a niche with relatively high switching costs and differentiation driven by data breadth, freshness, workflow integration, and analytical depth. The company’s positioning depends on the quality of its proprietary datasets, its use of AI and natural language processing, and the human research layer used to validate and enrich records. In practical terms, its moat is less about scale in the consumer sense and more about being a trusted source of healthcare commercial intelligence for enterprise customers. Although the company has a global footprint, the United States remains its principal market and the main engine of revenue generation.
Recent developments are important for investors. On February 26, 2026, Definitive Healthcare reported full-year 2025 results, with annual revenue of $241.5 million and improved adjusted profitability versus prior periods, while still recording material goodwill impairment charges. The company also continued to refresh and extend its product stack, including a broader push into adjacent analytics use cases. In addition, the company’s investor-relations site and SEC filings show ongoing insider transaction activity through Form 4 disclosures in 2025 and 2026, underlining that the stock remains actively followed by market participants on the NASDAQ.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
